Compare Caesars Entertainment Inc (CZR) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

Caesars Entertainment (CZR) trades at $29.62, down 1.5% on the day, with a bearish technical signal and recent quarterly earnings misses. The company reported a Q2 2026 loss of $0.30 per share, missing estimates, but revenue of $3.0 billion topped expectations. Fundamentals show a negative net income margin of -3.99% and high long-term debt of $12.03 billion, though operating cash flow remains strong at $1.30 billion in 2025. The pending acquisition by Tilman Fertitta for approximately $17.6 billion is a key development, as reported by the Wall Street Journal on July 28, 2026.

CZR presents a mixed outlook with acquisition potential offset by persistent losses and debt. The stock's low P/S ratio of 0.52 offers value, but investors face risks from earnings volatility and competitive pressures in the leisure sector. Analyst sentiment is cautious with 70% hold ratings, reflecting uncertainty around profitability improvements and integration post-acquisition.

DENTSPLY SIRONA (XRAY) trades at $11.32, down 2.92% today, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Net income remains negative, though margins show improvement. The stock is near its consensus price target of $11.50, with support at $11 and resistance at $12.

Outlook is cautious; while cost controls and new partnerships offer potential, persistent revenue declines and high debt levels pose significant risks. Analyst sentiment is predominantly Hold, reflecting uncertainty around the turnaround plan's success amid weak dental market demand.